<unk>  is an interleukin-2 that is FDA approved for the treatment of adults with metastatic renal cell carcinoma (metastatic RCC) and metastatic melanoma.. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include anaphylaxis, cellulitis, injection site necrosis, retroperitoneal hemorrhage, cardiomyopathy, cerebral hemorrhage, fatal endocarditis , hypertension, cholecystitis, colitis, gastritis, hepatitis, hepatosplenomegaly, intestinal obstruction, hyperthyroidism, neutropenia, myopathy, myositis, rhabdomyolysis, cerebral lesions, encephalopathy.
Aldesleukin
Interferon alfa-2a
Interferon alfa-2b
Ruxolitinib
Interferon Alfa-n3
Adalimumab
Nebacumab
Interferon